Oncopeptides reports Q3 2026 sales up 41% to SEK 28.5 million

Oncopeptides AB reported a 41% year-over-year increase in Q3 2026 sales to SEK 28.5 million, maintaining a 98% gross margin for the first nine months. Management cited Pepaxti's expansion into third-line treatment and glioblastoma proof-of-concept progress as growth catalysts, and continues to target positive commercial cash flow by 2027.

Detected & updated continuously · Source: Nebula